Phathom Pharmaceuticals Stock Today
| PHAT Stock | USD 8.97 0.12 1.32% |
Performance0 of 100
| Odds Of DistressOver 77
|
Phathom Pharmaceuticals is selling for under 8.97 as of the 28th of November 2024; that is 1.32 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 8.66. Phathom Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Phathom Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of October 2019 | Category Healthcare | Classification Health Care |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. The company has 68.38 M outstanding shares of which 14.66 M shares are at this time shorted by private and institutional investors with about 8.61 trading days to cover. More on Phathom Pharmaceuticals
Moving together with Phathom Stock
| 0.66 | VALN | Valneva SE ADR | PairCorr |
| 0.68 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.67 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Phathom Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Phathom Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Terrie Curran | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPhathom Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Phathom Pharmaceuticals' financial leverage. It provides some insight into what part of Phathom Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phathom Pharmaceuticals (PHAT) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Florham Park, NJ, United States, 07932 and employs 452 people. Phathom Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 613.35 M. Phathom Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 68.38 M outstanding shares of which 14.66 M shares are at this time shorted by private and institutional investors with about 8.61 trading days to cover.
Phathom Pharmaceuticals currently holds about 207.39 M in cash with (137.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39.
Check Phathom Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Phathom Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Phathom Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Phathom Pharmaceuticals. Please pay attention to any change in the institutional holdings of Phathom Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Phathom Ownership Details
Phathom Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Checkpoint Capital Lp | 2024-09-30 | 1.5 M | |
| Federated Hermes Inc | 2024-09-30 | 1.4 M | |
| Fmr Inc | 2024-09-30 | 1.3 M | |
| Portolan Capital Management, Llc | 2024-06-30 | 1.1 M | |
| Gw&k Investment Management, Llc | 2024-09-30 | 1.1 M | |
| Catalys Pacific Llc | 2024-09-30 | 1.1 M | |
| 683 Capital Management Llc | 2024-09-30 | 1 M | |
| Saturn V Capital Management Llc | 2024-09-30 | 874.6 K | |
| Propel Bio Management Llc | 2024-06-30 | 869.9 K | |
| Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 7.5 M | |
| Jennison Associates Llc | 2024-09-30 | 5.9 M |
Phathom Pharmaceuticals Historical Income Statement
Phathom Stock Against Markets
Phathom Pharmaceuticals Corporate Management
| Anthony Guzzo | Chief Officer | Profile | |
| Joseph JD | Chief Officer | Profile | |
| Tom Harris | Chief Officer | Profile | |
| Martin Gilligan | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile | |
| David Socks | CoFounder Director | Profile |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.